Editas Medicine
EDIT
249 hedge funds and large institutions have $465M invested in Editas Medicine in 2022 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 63 increasing their positions, 67 reducing their positions, and 53 closing their positions.
45% more call options, than puts
Call options by funds: $15.7M | Put options by funds: $10.8M
6% more ownership
Funds ownership: 70.2% → 76.2% (+6%)
6% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 67
6% less funds holding
Funds holding: 265 → 249 (-16)
21% less capital invested
Capital invested by funds: $592M → $465M (-$127M)
23% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$31.5M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$22.8M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$4.42M |
| 4 |
BlackRock
New York
|
+$3.91M |
| 5 |
D.E. Shaw & Co
New York
|
+$3.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$4.61M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
-$4.36M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$4.36M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.06M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$2.94M |
EDIT Hedge Fund Activity: Q4 2022 in Review
249 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q4 2022, worth a combined $465M — down 21% from $592M a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of EDIT and 41 opened new positions — a net loss of 12 holders — while 67 trimmed existing stakes and 63 added.
The largest buyer was State Street, adding an estimated $31.5M. The largest seller was Cubist Systematic Strategies, exiting entirely with an estimated $4.61M sold.
- 249 institutional investors held Editas Medicine (EDIT) as of Q4 2022, down from 265 in Q3 2022.
- Funds reported $465M of Editas Medicine stock for Q4 2022, down 21% quarter-over-quarter.
- 41 funds opened new Editas Medicine positions in Q4 2022 and 53 closed out, a net change of -12 holders.
- The largest Editas Medicine buyer in Q4 2022 was State Street, an estimated $31.5M added.
- The largest Editas Medicine seller in Q4 2022 was Cubist Systematic Strategies, an estimated $4.61M sold.
Based on aggregated 13F filings for Q4 2022.